ELANCO ANIMAL HEALTH INC (ELAN) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:ELAN - US28414H1032 - Common Stock
ELAN Key Statistics, Chart & Performance
The current stock price of ELAN is 23.05 USD. In the past month the price increased by 4.82%. In the past year, price increased by 101.66%.
ELAN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.36 | 984.62B | ||
| JNJ | JOHNSON & JOHNSON | 19.68 | 492.24B | ||
| MRK | MERCK & CO. INC. | 12.2 | 266.67B | ||
| PFE | PFIZER INC | 7.87 | 143.11B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.09 | 108.02B | ||
| ZTS | ZOETIS INC | 20.41 | 57.01B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.65 | 22.89B | ||
| VTRS | VIATRIS INC | 5.31 | 14.25B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.64B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.56B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.57B | ||
| GPCR | STRUCTURE THERAPEUTICS INC | N/A | 3.81B |
Related stock screener links
About ELAN
Company Profile
Elanco Animal Health, Inc. develops, manufactures, and markets products for pets and farm animals. The company is headquartered in Indianapolis, Indiana and currently employs 9,000 full-time employees. The company went IPO on 2018-09-20. The firm's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). The company has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The firm's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.
Company Info
ELANCO ANIMAL HEALTH INC
450 Elanco Circle
Indianapolis INDIANA 46140 US
CEO: Jeffrey N. Simmons
Employees: 9225
Phone: 18773526261
ELANCO ANIMAL HEALTH INC / ELAN FAQ
What does ELANCO ANIMAL HEALTH INC do?
Elanco Animal Health, Inc. develops, manufactures, and markets products for pets and farm animals. The company is headquartered in Indianapolis, Indiana and currently employs 9,000 full-time employees. The company went IPO on 2018-09-20. The firm's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). The company has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The firm's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.
Can you provide the latest stock price for ELANCO ANIMAL HEALTH INC?
The current stock price of ELAN is 23.05 USD. The price increased by 2.35% in the last trading session.
What is the dividend status of ELANCO ANIMAL HEALTH INC?
ELAN does not pay a dividend.
What is the ChartMill technical and fundamental rating of ELAN stock?
ELAN has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
On which exchange is ELAN stock listed?
ELAN stock is listed on the New York Stock Exchange exchange.
Is ELANCO ANIMAL HEALTH INC (ELAN) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ELAN.
Is ELANCO ANIMAL HEALTH INC (ELAN) expected to grow?
The Revenue of ELANCO ANIMAL HEALTH INC (ELAN) is expected to grow by 5.5% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
ELAN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ELAN. When comparing the yearly performance of all stocks, ELAN is one of the better performing stocks in the market, outperforming 94.21% of all stocks.
ELAN Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ELAN. ELAN has a medium profitability rating, but doesn't score so well on its financial health evaluation.
ELAN Financial Highlights
Over the last trailing twelve months ELAN reported a non-GAAP Earnings per Share(EPS) of 0.96. The EPS increased by 12.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.78% | ||
| ROA | 0.27% | ||
| ROE | 0.53% | ||
| Debt/Equity | 0.59 |
ELAN Forecast & Estimates
21 analysts have analysed ELAN and the average price target is 26.05 USD. This implies a price increase of 13.01% is expected in the next year compared to the current price of 23.05.
For the next year, analysts expect an EPS growth of 5.08% and a revenue growth 5.5% for ELAN